PMC4423504_01
Changing trends of dasatinib dosage and platelet count from April 17, 2014 to March 13, 2015.
ott-8-955Fig1.jpg
PMC4423504_01_ott-8-955Fig1.jpg
f1-ott-8-955
After taking dasatinib, severe myelosuppression occurred in this patient, especially the platelet count, so we adjusted the dosage of dasatinib considering both the disease and the patient's count of platelet (Figure 1).